Drugs / actinium-225-macropa-pelgifatamab
actinium-225-macropa-pelgifatamab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06052306 | Sep 2023 → Jun 2027 expected | castration-resistant prostate carcinoma | Bayer | Active not recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | actinium-225-macropa-pelgifatamab | “The study treatment actinium-225-macropa-pelgifatamab (also called 225Ac-pelgi or BAY3546828) is a new type of treatment under development for participants with mCRPC who have...” NCT06052306 ↗ |
| Known as | 225Ac-macropa-pelgifatamab | “The in vitro characteristics and in vivo biodistribution, antitumor efficacy, and tolerability of 225Ac-macropa-pelgifatamab (225Ac-pelgi) and other TATs were investigated in...” PMID 38593212 ↗ Jun 2024 |
| Known as | 225Ac-pelgi | “The study treatment actinium-225-macropa-pelgifatamab (also called 225Ac-pelgi or BAY3546828) is a new type of treatment under development for participants with mCRPC who have...” NCT06052306 ↗ |
| Known as | BAY 3546828 | “A Phase 1 Open-label, First-in-human, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Actinium-225-macropa-pelgifatamab (BAY...” NCT06052306 ↗ |
| Action | Deplete | “it kills the nearby (cancer) cells that express PSMA.” NCT06052306 ↗ |
| Modality | Monoclonal antibody | “the PSMA antibody pelgifatamab covalently linked to a macropa chelator and labeled with actinium-225” PMID 38593212 ↗ Jun 2024 |
| Route | Intravenous | “Intravenous (IV) infusion on Day 1 of each cycle.” NCT06052306 ↗ |